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Highlights of primary biliary cirrhosis
Primary biliary cirrhosis (PBC) is an autoimmune chronic 
cholestatic liver disease, histopathologically charac-
terized by portal inflammation and immune-mediated 
destruction of the intrahepatic bile ducts within the 
portal tracts and epithelioid granulomas around damaged 
bile ducts. e loss of bile ducts leads to decreased bile 
secretion and the retention of toxic substances within the 
liver, resulting in further hepatic damage, fibrosis, 
cirrhosis and, eventually, liver failure [1]. Serologically, 
PBC is characterized by the presence of antimito-
chondrial antibodies (AMAs) -which are present in 90 to 
95% of patients and are often detectable years before 
clinical signs appear [2]; high plasma levels of immuno-
globulin M (IgM) [3]; and high-titer antibodies against 
nuclear antigens (ANAs). It is estimated that 30 to 50% of 
patients also have specific ANAs, including antibodies to 
nucleoporin p62 (Nup62), a glycoprotein located within 
the nuclear pore complex (NPC) [4]. ese antibodies are 
associated with more severe forms of the disease. While 
AMA presence is often used for diagnostic purposes, 
ANAs and Nup62 could be linked to prognosis and are 
helpful tools in the management of patients with PBC, 
particularly in the AMA-negative subgroup [5,6].
PBC primarily affects middle-aged women, with a 
female/male ratio of 9/1, a characteristic shared by other 
autoimmune diseases [7]. It also seems to be more 
common among the first-degree relatives of patients 
[8,9]. Studies of the annual incidence and prevalence of 
PBC in different geographical areas suggest the impact of 
ethnic influences, environmental factors and the non-
uniform criteria used for the diagnosis of PBC. PBC still 
appears to be more frequent in northern Europe and the 
United States, but overall the incidence ranges between 
0.7 and 49 per million population, while the prevalence is 
between 6.7 and 402 cases per million population [10], 
thus making PBC a rare disease according to the 2002 
Rare Disease Act. Several studies have reported a sub-
stantial increase in PBC prevalence and incidence over 
recent decades, similar to other autoimmune diseases 
[11]. is is mostly due to a better and earlier recognition 
of disease, and to more sensitive diagnostic procedures 
[12]. PBC is now diagnosed at an earlier stage in its 
clinical course than it was in the past, with 50 to 60% of 
patients asymptomatic at diagnosis, and one-third of 
them remaining symptom free for many years.
e diagnosis of PBC is currently based on three 
criteria: serological positivity for AMA, a cholestatic 
biochemical picture with elevated levels of serum alkaline 
phosphatase and γ glutamyl transferase lasting for over 
6  months, and histological features compatible with the 
presence of the disease. A probable diagnosis requires the 
presence of two of these three criteria, and a definite 
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diagnosis requires all three. In about 5 to 10% of cases, a 
compatible liver biopsy together with biochemical 
cholestatic features of PBC but in the absence of AMA is 
seen. This connotes the condition known as AMA­nega­
tive PBC or ‘autoimmune cholangiopathy’, now con­
sidered a nosological entity, practically identical to PBC 
apart from the serological profile [13,14]. From a clinical 
standpoint, PBC can be divided into four stages: pre­
sympto matic (characterized by AMA seropositivity with 
abnormal liver tests and without symptoms), asymp to­
matic (AMA seropositivity and abnormal liver tests), 
symptomatic (patients present PBC­related symptoms), 
and decompensated (symptoms and complications of 
end­stage liver disease).
The natural history of PBC is characteristically 
associated with important variations: while some patients 
present with a slowly progressive disease, others have an 
early onset of complications. A recent case­control study 
[15] showed not only that PBC is associated with other 
autoimmune diseases in 30% of cases (Raynaud’s syn­
drome in 12%, Sjögren syndrome in 10%, rheumatoid 
arthritis in 10%, autoimmune thyroid disease in 9%, 
systemic lupus erythematosus (SLE) in 3% and sclero­
derma in 2% of cases), but also that this association may be 
considered a negative prognostic factor. Finally, although 
several studies have suggested that the early use of 
ursodeoxycholic acid has a positive impact on prognosis, 
none of the current models of treatment have shown a 
definitive impact on the natural history of PBC [16], and at 
the end stage of the disease, liver transplantation is the 
only effective mode of treatment [17].
Etiopathogenesis of PBC
Factors leading to PBC onset remain poorly understood, 
but several lines of evidence suggest that immune­
mediated mechanisms play a crucial role. Numerous 
similarities exist between PBC and other autoimmune 
disorders, including female predominance, increased 
prevalence in subjects with a family history of PBC, and 
frequent coexistence with other autoimmune diseases. 
The tissue selectivity of the immune attack is particular 
to PBC, as is the poor responsiveness of patients to 
immune suppression. In addition, the breakdown of 
immune tolerance against mitochondrial and nuclear 
self­antigens is also unique to PBC.
Cholangiocytes play an important role in the 
pathogenesis of PBC and may account for the high tissue 
specificity. Indeed, the PBC paradox is that the damage is 
highly localized and only targets the lining of the small 
and medium­sized intrahepatic bile ducts, despite 
ubiquitous expression of the autoantigens [18]. The most 
recent data on apoptosis may provide the key to these 
observations [19]. Ultimately, the onset of PBC requires 
two components: a permissive genetic background and 
an environmental trigger. While the discussion of this 
latter aspect goes beyond the aims of the present article 
[20], we will now review the numerous studies that asso­
ciate PBC onset with genetic variants and polymorphisms.
Putative genomic associations in PBC
PBC is more frequent in relatives of affected individuals, 
and the term ‘familial PBC’ has been coined to indicate 
families that have more than one case. Variable rates of 
familial PBC are seen in different geographical regions, 
possibly due to different methods of case definition. In 
general, data indicate that 1 to 6% of PBC cases have at 
least one other family member presenting with the 
disease [21]. Such familial prevalence rates are signifi­
cantly higher than general population prevalence esti­
mates, thus indicating a genetic predisposition to the 
disease. However, the difficulty of evaluating these data 
is that prevalence rates in the general population are 
still uncertain and control groups are not always 
included in family studies. The concordance rate 
observed among monozygotic twins for PBC is 63%, 
among the highest reported in auto immune diseases. 
This reinforces the concept of an important genetic 
factor in susceptibility to this disease [21], but also 
highlights the necessity for an environmental insult, be 
it chemical, bacterial, or viral [22].
Several studies have attempted to identify the genes 
associated with PBC. No family study of genetic linkage 
has been performed, possibly because PBC is a relatively 
rare disease and it is therefore difficult to obtain DNA 
samples from a large number of representative families. 
All available studies were designed in a controlled cross­
sectional fashion, but were prone to multiple sampling 
errors and biases caused by incorrect estimations. A 
multi­hit genetic model seems to apply to PBC, with 
different genetic variants conferring susceptibility (first 
hit) and others influencing disease progression (second 
hit). For this reason, most authors investigating genetic 
factors in PBC have studied their role in susceptibility to 
the disease (comparing allele and genotype frequencies in 
patients and controls), as well as in its severity (through 
the analysis of clinical characteristics of patients carrying 
different geno types or alleles). No definitive association 
of PBC suscepti bility or progression could be identified 
in these studies [23]. When an association was found, it 
has proved to be weak or limited to specific geographical 
regions. We note that this also applies to the study of the 
variants of major histocompatibility complex (MHC; 
including type I, II, and III loci), in which, unlike most 
autoimmune diseases, reported associations were often 
weak [24] or limited to specific geographical areas [25]. 
Similar findings were also reported from the study of the 
genetic variants of immuno modulatory molecules (such 
as chemokines, receptors), enzymes producing vasoactive 
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compounds, and bile­acid transporters [9]. The proposed 
associations are summarized next.
Major histocompatibility complex and PBC
Strong associations with specific MHC human leukocyte 
antigen (HLA) alleles have been reported in many auto­
immune diseases, in some cases constituting the gold­
standard for the diagnosis of otherwise undetermined 
cases [26].
Studies performed on small cohorts of subjects (between 
21 and 75) have examined the association between HLA 
class I molecules and PBC susceptibility [27­33], but the 
conclusions of these early reports were affected by several 
major flaws, including limited statistical power, and 
technological problems for an accurate allele analysis. 
Nevertheless, our group reported that PBC is associated 
with various HLA­B alleles in a small proportion of 
patients [34]. It is possible that the positive association 
might be secondary to linkage disequilibrium. Based on 
the available data, we should therefore regard PBC 
associations with HLA class I genes as weak.
The association of HLA class II alleles with PBC has 
been widely studied in Caucasian and Asian patient 
cohorts. In studies from Germany, Spain, Sweden, and 
the United States, HLA-DR8 (DRB1*08) was found with 
significantly higher frequency in patients with PBC 
compared to controls; cumulatively, data aggregation 
indicates that DR8 might constitute a risk factor for PBC 
among Caucasians [32,35­38]. In 2001, data from 
Newcastle, UK demonstrated that the linkage of 
DQA1*0401 and DR8-DQB1*0402 is associated with PBC 
progression and not susceptibility [39]. Other studies in 
non­British European populations have not confirmed 
this association [30,33,34,40,41]. Moreover, other Euro­
pean studies suggested significant associations of PBC 
with DR3 [27,33] and DPB1*0301 [42], while the most 
recent study from the United States demonstrated an 
association between the DRB1*08-DQA1*0401-DQB1*04 
haplotype and PBC, albeit in a minority of patients [38]. 
Finally, studies from Japan failed to provide a consistent 
picture of HLA class II associations with PBC [28,29,43]. 
Interestingly, in a large series of Italian patients with PBC 
and controls, we observed a protective effect of the 
DRB1*11 allele in PBC, which was later confirmed in a 
larger set of patients and controls along with a positive 
association with DRB1*08 [25].
In summary, we can conclude that the picture of HLA 
class II involvement in PBC is quite complex. We could 
assume that, similar to the epidemiological data, the 
genetic background in PBC could be associated with a 
geographical pattern.
Data from association studies of polymorphisms of 
tumor necrosis factor (TNF)­α in PBC are conflicting 
and a cautious interpretation is encouraged [44]. A 
polymorphism of the gene promoter region produces the 
more frequent variant TNF1, and the less frequent 
variant TNF2 [45], with TNF2 associated with increased 
transcription [46­48]. The prevalence of the TNF2 allele 
was reportedly protective against PBC onset [49] while 
two other studies independently failed to detect any 
difference in genotype distributions between patients and 
controls [50,51]. In the study from Tanaka and colleagues, 
heterozygous patients had a significantly worse prognosis 
compared to homozygous TNF1/TNF1 patients [50], as 
indicated by higher Mayo score value, currently the only 
validated index for PBC [52]. However, a study from 
Newcastle, UK did not confirm this alleged association 
[51]. Similarly, data obtained from Scottish, Brazilian, 
and Chinese patient cohorts with PBC [41,53,54], and 
from a small population of patients undergoing liver 
transplantation for end­stage PBC [55], revealed no 
association of TNF genotypes with disease susceptibility 
or onset.
High­throughput novel technologies have made the 
study of single nucleotide polymorphisms (SNPs) of candi­
date genes the method of choice for association studies in 
PBC. The analysis of SNPs can define the linkage of 
specific loci or neighboring regions with disease traits. We 
note that, in addition to the general considera tions 
expressed above on the choice of candidate genes and 
populations, the study of SNPs should be more focused on 
coding variants (that is, with demonstrated effects on 
phenotype) of genes, although this might exclude other 
SNPs that are possibly in linkage disequilibrium with genes 
that are important for disease onset [56].
Non-MHC genes in PBC
Most studies of SNPs in PBC have been dedicated to 
molecules involved in regulating the immune response, 
thus hypothesizing that genomic differences at these 
levels might confer susceptibility to the loss of tolerance 
or to an aberrant immune response. Based on the 
expression of cytotoxic T lymphocyte antigen­4 (CTLA-4) 
by T cells following activation and the regulatory effect of 
this molecule on peripheral T cell responses, SNPs of 
CTLA-4 were suggested as factors facilitating the 
breakdown of tolerance. Accordingly, the coding 49A>G 
SNP was found associated with PBC in a large British 
study [57] and in 77 Chinese patients with PBC [58], 
while a smaller study from Brazil failed to confirm the 
association [41]. Several studies were further dedicated 
to SNPs of interleukins (ILs), based on their critical role 
in the regulation of the immune response. Prompted by 
experimental data such as its dysregulated production by 
monocytes in PBC [59], SNPs of IL-1 were studied. First, 
a study from the UK reported a significantly higher 
frequency of the IL-1B*1,1 genotype in patients with PBC 
compared to controls. The difference in the IL-1B*1,1 
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genotype distribution was even more marked in patients 
with early­stage disease, thus possibly indicating that 
IL-1 alleles might influence disease progression [39]. The 
lack of association with PBC onset was also inde pen­
dently confirmed by Hungarian [60] and Chinese [61] 
researchers. The latter group, however, more recently 
described an association of PBC with the IL1-RN intron 
genotype, comparing frequencies in 77 patients with PBC 
and 160 controls [62]. Further, based on experi mental 
evidence of cytokine profiles and their involve ment in the 
development of T helper 1 cell responses, SNPs of the 
promoter region of the IL-10 gene were also analyzed in 
patients with PBC and controls [53,62,63]. Data from 
Italian and Japanese series demonstrated that both 
groups presented a higher prevalence of the ­1082G/G 
genotype [63]. Such association was not confirmed in 77 
Chinese patients with PBC [61,62].
SNPs of the 1,25­dihydroxyvitamin D receptor (VDR) 
gene have been investigated in several studies, based on 
the dual role of vitamin D in the regulation of bone 
metabolism and inflammation. Accelerated bone loss 
rates in patients with prolonged cholestasis (as in PBC) 
have been repeatedly reported, sometimes with conflict­
ing results, and in some cases with less than rigorous 
experimental designs. A significant association between 
BsmII polymorphisms of VDR and PBC was reported in 
patients with PBC from Germany, Hungary, and China 
[60,64­66], while the proposed association with bone loss 
[67] was not reproduced [68]. We believe that differences 
in the VDR gene might unravel further potential 
scenarios to help explain the infrequency of PBC in 
African­American women [69], and could in turn 
support a possible role for sunlight exposure in PBC 
onset. Although fascinating, this assumption remains a 
hypothesis, yet to be confirmed.
Molecules responsible for bile acid transport and 
excretion in the biliary tree have been obvious targets in 
the search for genomic determinants of PBC onset. 
Interestingly, SNPs and mutation of ATP binding cassette 
(ABC) transporters involved in the secretion of bile from 
the hepatocyte [70] have been associated with intra­
hepatic cholestasis of pregnancy [71], somehow repro­
duc ing the clinical picture observed in PBC. Pauli­
Magnus and colleagues [70] have carried out gene 
sequenc ing to investigate the variants of genes coding for 
the two main ABC transporters, identifying 45 ABCB11 
and 46 ABCB4 variants, but found that no mutation was 
associated with PBC. More recently, a similar lack of 
association data was reported for the anion exchanger 
gene SLC4A2 [72].
Prompted by the xenobiotic PBC theory [21], we also 
investigated whether genetic variants leading to different 
xenobiotic metabolism or transport might in turn account 
for an increased risk of developing the disease. We 
therefore genotyped several polymorphisms of enzymes 
involved in the transport and metabolism of xenobiotics in 
169 patients with PBC and 225 healthy controls [73]. Data 
demonstrated that no polymorphism was associated with 
PBC susceptibility, while a weak association of the 
cytochrome P450 CYP2E1 c2 allele with disease severity 
was observed in a small subgroup of patients.
Recent studies demonstrated that copy number 
variations are found in patients with PBC, as in the case 
of an intragenic region on chromosome 4 called MER115. 
This was identified during investigation regarding micro­
bial agents using representational difference analysis [74]. 
The observation that keratin mutations are more 
frequently encountered in PBC cases and reflect the 
disease phenotype [75] is also of note.
Genome-wide studies come of age
More recently, the first genome­wide case­control 
association study was reported in PBC cases from 
Canada and the US [76] and reported significant associa­
tions of PBC with IL-12A, IL-12RB2, and STAT4 poly­
morphisms. The study benefited from sufficient statistical 
power due to the inclusion of 536 patients with PBC and 
1,536 controls genotyped for over 300,000 SNPs, and has 
to be regarded as the current state­of­the­art study into 
the genetic basis of PBC, although new and more 
powerful genotyping tools are becoming available. The 
role of IL-12 was most recently supported by experi­
mental data from our group demonstrating in a PBC 
animal model that the IL-12p40 gene is crucial to auto­
immunity development [77], thus proving an ideal link 
between genomic studies and disease pathogenesis, with 
potential therapeutic implications
The sex chromosome connection in PBC
Similar to other autoimmune diseases commonly 
diagnosed in women after the menopause [78], fetal 
microchimerism has been suggested in PBC, with the 
hypothesis of higher prevalence of small amounts of fetal 
(paternal) DNA found in mothers with PBC [79]. First, it 
was suggested that the presence of fetal DNA in the liver 
of affected women years after pregnancy might 
predispose to PBC [80]; however, independent findings 
have not confirmed this hypothesis [81,82]. Genes on the 
X chromosome are critical to the maintenance of physio­
logical sex hormone levels and, more importantly, of 
immune responsiveness [83]. Invernizzi and colleagues 
reported age­dependent enhanced monosomy X in the 
peripheral white blood cells of women with PBC [84], 
and later data suggested that the X chromosome loss is 
preferential (that is, it more commonly involves the 
paternal or maternal chromosome) [85]. This observation 
seems to indicate a polygenic model for PBC, with an 
X­linked major locus of susceptibility in which genes 
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escaping inactivation are the major candidates [86]. This 
is well represented in the recent literature on conditions 
characterized by major sex chromosome defects [87­90].
Is it prime time for epigenetics?
Studying the genetic basis of human diseases may yield 
direct data; however, uncovering the genetic causes of 
diseases may not help in reversing the disease process 
itself. In contrast, epigenetic mechanisms governing 
diseases seem more malleable than genetic sequences, 
and if causal epigenetic changes are uncovered, they may 
be potentially reversed through pharmacological inter­
ventions or changing environmental stimuli [91]. There is 
an emerging efficacy for cancer treatments in the use of 
‘epigenetic drugs’ that inhibit DNA methylation or 
histone deacetylation [92], so such strategies may be useful 
to treat other human diseases with epigenetic bases.
Studies on the epigenetics of autoimmunity have been 
limited to SLE and rheumatoid arthritis, while no data 
are currently available for PBC [93]. In 1997, Huang and 
colleagues [94] failed to observe significant differences in 
X chromosome inactivation in four monozygotic twins 
discordant for SLE, although only one fully inactivated 
gene (androgen receptor) was evaluated in this work. On 
the other hand, Richardson and colleagues [95] demon­
strated DNA hypomethylation of T lymphocytes of 
patients affected by SLE. In association with the reportedly 
higher numbers of CD4+ lymphocytes in females com­
pared to males [96], these data encouraged further 
analysis in the field. Drugs such as hydralazine and 
procainamide inhibit T­cell DNA methylation and induce 
a murine lupus­like syndrome characterized by the 
presence of anti­double strand DNA (anti­dsDNA) 
antibodies and glomerulonephritis [97]. Recently, the 
effect of methylation on single molecules was demon­
strated; Oelke and colleagues [98] reported the similar in 
vitro behavior of SLE T cells and healthy T cells treated 
with DNA methylation inhibitors. In particular, both 
lymphocyte populations overexpressed CD70, leading to 
an increased production of IgG [98]. Taken together, 
these findings, obtained in a different yet female­
predominant autoimmune disease such as SLE, support 
the potential role of epigenetics in PBC, as represented 
by microRNA data [99].
Concluding remarks and future developments
Following the review of the numerous published studies 
on the genomic associations in PBC, three major 
questions remain. Firstly, how do these new variants 
increase our understanding of the disease or lead to new 
insights about disease pathogenesis, treatment or 
manage ment? This constitutes possibly the most promi­
nent weakness of the available studies in PBC genetics, as 
the candidate genes were often chosen based on a weak 
background. This limitation can be overtaken with 
rigorous approaches based on solid associations, as in the 
case of IL-12. Second, how have these variants impacted 
on other autoimmune diseases with a genetic compo­
nent? While other autoimmune diseases cannot be 
directly compared to PBC, the presence of similar genetic 
associations between them is likely, as in the case of 
STAT4 in SLE and rheumatoid arthritis [100]. The third 
and most difficult question is related to the potential 
clinical applications of these variants for personalized 
medicine in PBC [101]. We suggest that only the inte­
gration of genomic data with findings from epigenetics 
and microRNA research [102], possibly through the use 
of antisense oligomers, will provide a pragmatic use for 
the gathered evidence.
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